{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-15",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Fremont",
      "state": "CA",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Devices",
      "event_id": "74982",
      "recalling_firm": "Microgenics Corporation",
      "address_1": "46500 Kato Rd",
      "address_2": "N/A",
      "postal_code": "94538-7310",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Worldwide Distribution - US Nationwide in the states of KY, CA, NY, DC, NC, TX, IL, OH, IL, FL, IK, IA, MS and countries of Mexico, Taiwan, Guatemala, Malaysia, Argentina, Dominican Republic, Philippines, Germany, Australia.",
      "recall_number": "Z-0008-2017",
      "product_description": "Thermo Scientific QMS Everolimus Assay;  Model number:  0380000 (US Distribution);  0373852 (Foreign Distribution)    Product Usage:  The QMS Everolimus Assay is intended for the quantitative determination of Everolimus, in human whole blood on automated clinical chemistry analyzers. The results obtained are used as an aid in the management of kidney and liver transplant patients receiving Everolimus therapy. This in vitro diagnostic device is intended for clinical laboratory use only. The QMS Everolimus assay is intended to be used as an aid in the management of patients receiving everolimus therapy for those organ transplant procedures indicated in the chart for each specific country.",
      "product_quantity": "163 kits in US, 669 kits worldwide - toatal 831.",
      "reason_for_recall": "A reagent stability issue (still under investigation) causes less separation in the calibration curve, which affects results across the entire range.  For controls, maximum bias of +/- 35% for low levels, +/- 33% for mid-range levels, and +/- 47% for high levels is observed.  Bias in patient samples ranges from -15.7% to +5.2% with an average bias of -5.6% when comparing the QMS everolimus assay to an everolimus LC-MS reference method.  Patient samples across the measuring range \u0013 sub-therapeutic, therapeutic, and supra-therapeutic \u0013 could be affected.",
      "recall_initiation_date": "20160815",
      "center_classification_date": "20161003",
      "termination_date": "20170104",
      "report_date": "20161012",
      "code_info": "Lot number: 72258049, Expiry date: 07/31/2017;  Lot number: 72258007, Expiry date 07/31/2017."
    }
  ]
}